492TiP A phase I study of synthetic lethal, IDE397 (MAT2A inhibitor) as a monotherapy and in combination with chemotherapy in advanced solid tumors harboring MTAP deletion
Work
Year: 2022
Type: article
Source: Annals of Oncology
Authors Melissa L. Johnson, J. Rodon, Raid Aljumaily, Miguel A. Villalona‐Calero, Erkut Borazanci +13 more
Institutions Sarah Cannon, The University of Texas MD Anderson Cancer Center, University of Oklahoma, City Of Hope National Medical Center, HonorHealth +10 more
Cites:
Cited by: 2
Related to: 10
FWCI: 0.235
Citation percentile (by year/subfield): 44.88
Subfield: Molecular Biology
Domain: Life Sciences
Sustainable Development Goals No poverty, Good health and well-being
Open Access status: bronze